JAHA:他汀类药物使用与颈动脉血管重建术后心血管事件的关系

2018-08-08 xing.T MedSci原创

由此可见,连续接受他汀类药物治疗与明显的颈动脉疾病患者长期不良心血管事件风险降低25%相关。除了其他支持性证据外,在接受颈动脉血运重建术的患者中应考虑采用他汀类药物治疗,并且需要努力增加这类治疗不足人群的他汀类药物使用比例。

他汀类药物通常用于预防血管事件; 然而,他汀类药物在非冠状动脉粥样硬化患者中尚未充分利用。近日,血管疾病领域权威杂志JAHA上发表了一篇研究文章,研究人员试图明确他汀类药物在颈动脉疾病患者中的使用率,并探究他汀类药物治疗与颈动脉血运重建术后结局之间的关系。

在这项人群水平的回顾性队列研究中,研究人员确定了所有在加拿大安大略省(2002-2014)接受颈动脉内膜切除术或支架植入术的年龄≥66岁的个体。该研究的主要结局是1年卒中心肌梗死或死亡(主要不良心脏和脑血管事件)的复合事件。研究人员还评估了5年风险,并使用基于倾向得分的治疗加权反向概率计算了调整后的风险比。

接受颈动脉血运重建的10723例患者(73.6%)中共有7893例患者接受了术前他汀类药物治疗; 7384名患者(68.9%)接受了中等剂量或高剂量他汀类药物治疗。他汀类药物使用者1年主要心脏和脑血管事件的复合事件发生率较低(校正后的风险比:0.76; 95%置信区间为0.70-0.83)。在颈动脉手术后持续接受长期他汀类药物治疗的患者在5年时继续经历显著较低的主要心脏和脑血管不良事件风险(校正后风险比:0.75,95%置信区间为0.71-0.80)。无论颈动脉血运重建术、颈动脉症状状态或他汀类药物剂量如何,研究人员均观察到与他汀类药物使用的有益关联。

由此可见,连续接受他汀类药物治疗与明显的颈动脉疾病患者长期不良心血管事件风险降低25%相关。除了其他支持性证据外,在接受颈动脉血运重建术的患者中应考虑采用他汀类药物治疗,并且需要努力增加这类治疗不足人群的他汀类药物使用比例。

原始出处:

Mohamad A.et al. Association Between Statin Use and Cardiovascular Events After Carotid Artery Revascularization.JAHA.2018. https://www.ahajournals.org/doi/full/10.1161/JAHA.118.009745

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1643557, encodeId=4c61164355e06, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Sat Oct 20 10:10:00 CST 2018, time=2018-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843522, encodeId=fce1184352222, content=<a href='/topic/show?id=dab8100523bb' target=_blank style='color:#2F92EE;'>#颈动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100523, encryptionId=dab8100523bb, topicName=颈动脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Thu Mar 21 19:10:00 CST 2019, time=2019-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820295, encodeId=4656182029589, content=<a href='/topic/show?id=cc4b10056431' target=_blank style='color:#2F92EE;'>#颈动脉血管重建术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100564, encryptionId=cc4b10056431, topicName=颈动脉血管重建术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Sun Mar 24 06:10:00 CST 2019, time=2019-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708989, encodeId=3bd21e08989ed, content=<a href='/topic/show?id=1502333250f' target=_blank style='color:#2F92EE;'>#动脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33325, encryptionId=1502333250f, topicName=动脉血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=048f31575940, createdName=ms9833124466084992, createdTime=Sun Aug 19 11:10:00 CST 2018, time=2018-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971567, encodeId=243219e1567ff, content=<a href='/topic/show?id=797b8e67141' target=_blank style='color:#2F92EE;'>#药物使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87671, encryptionId=797b8e67141, topicName=药物使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Sat Mar 02 06:10:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044513, encodeId=c2fb20445137b, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Mar 21 04:10:00 CST 2019, time=2019-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340410, encodeId=76153404103d, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Thu Aug 23 22:16:39 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267885, encodeId=5817126e885e0, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Aug 10 09:10:00 CST 2018, time=2018-08-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1643557, encodeId=4c61164355e06, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Sat Oct 20 10:10:00 CST 2018, time=2018-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843522, encodeId=fce1184352222, content=<a href='/topic/show?id=dab8100523bb' target=_blank style='color:#2F92EE;'>#颈动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100523, encryptionId=dab8100523bb, topicName=颈动脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Thu Mar 21 19:10:00 CST 2019, time=2019-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820295, encodeId=4656182029589, content=<a href='/topic/show?id=cc4b10056431' target=_blank style='color:#2F92EE;'>#颈动脉血管重建术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100564, encryptionId=cc4b10056431, topicName=颈动脉血管重建术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Sun Mar 24 06:10:00 CST 2019, time=2019-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708989, encodeId=3bd21e08989ed, content=<a href='/topic/show?id=1502333250f' target=_blank style='color:#2F92EE;'>#动脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33325, encryptionId=1502333250f, topicName=动脉血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=048f31575940, createdName=ms9833124466084992, createdTime=Sun Aug 19 11:10:00 CST 2018, time=2018-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971567, encodeId=243219e1567ff, content=<a href='/topic/show?id=797b8e67141' target=_blank style='color:#2F92EE;'>#药物使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87671, encryptionId=797b8e67141, topicName=药物使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Sat Mar 02 06:10:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044513, encodeId=c2fb20445137b, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Mar 21 04:10:00 CST 2019, time=2019-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340410, encodeId=76153404103d, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Thu Aug 23 22:16:39 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267885, encodeId=5817126e885e0, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Aug 10 09:10:00 CST 2018, time=2018-08-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1643557, encodeId=4c61164355e06, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Sat Oct 20 10:10:00 CST 2018, time=2018-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843522, encodeId=fce1184352222, content=<a href='/topic/show?id=dab8100523bb' target=_blank style='color:#2F92EE;'>#颈动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100523, encryptionId=dab8100523bb, topicName=颈动脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Thu Mar 21 19:10:00 CST 2019, time=2019-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820295, encodeId=4656182029589, content=<a href='/topic/show?id=cc4b10056431' target=_blank style='color:#2F92EE;'>#颈动脉血管重建术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100564, encryptionId=cc4b10056431, topicName=颈动脉血管重建术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Sun Mar 24 06:10:00 CST 2019, time=2019-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708989, encodeId=3bd21e08989ed, content=<a href='/topic/show?id=1502333250f' target=_blank style='color:#2F92EE;'>#动脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33325, encryptionId=1502333250f, topicName=动脉血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=048f31575940, createdName=ms9833124466084992, createdTime=Sun Aug 19 11:10:00 CST 2018, time=2018-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971567, encodeId=243219e1567ff, content=<a href='/topic/show?id=797b8e67141' target=_blank style='color:#2F92EE;'>#药物使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87671, encryptionId=797b8e67141, topicName=药物使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Sat Mar 02 06:10:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044513, encodeId=c2fb20445137b, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Mar 21 04:10:00 CST 2019, time=2019-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340410, encodeId=76153404103d, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Thu Aug 23 22:16:39 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267885, encodeId=5817126e885e0, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Aug 10 09:10:00 CST 2018, time=2018-08-10, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1643557, encodeId=4c61164355e06, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Sat Oct 20 10:10:00 CST 2018, time=2018-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843522, encodeId=fce1184352222, content=<a href='/topic/show?id=dab8100523bb' target=_blank style='color:#2F92EE;'>#颈动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100523, encryptionId=dab8100523bb, topicName=颈动脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Thu Mar 21 19:10:00 CST 2019, time=2019-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820295, encodeId=4656182029589, content=<a href='/topic/show?id=cc4b10056431' target=_blank style='color:#2F92EE;'>#颈动脉血管重建术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100564, encryptionId=cc4b10056431, topicName=颈动脉血管重建术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Sun Mar 24 06:10:00 CST 2019, time=2019-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708989, encodeId=3bd21e08989ed, content=<a href='/topic/show?id=1502333250f' target=_blank style='color:#2F92EE;'>#动脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33325, encryptionId=1502333250f, topicName=动脉血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=048f31575940, createdName=ms9833124466084992, createdTime=Sun Aug 19 11:10:00 CST 2018, time=2018-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971567, encodeId=243219e1567ff, content=<a href='/topic/show?id=797b8e67141' target=_blank style='color:#2F92EE;'>#药物使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87671, encryptionId=797b8e67141, topicName=药物使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Sat Mar 02 06:10:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044513, encodeId=c2fb20445137b, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Mar 21 04:10:00 CST 2019, time=2019-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340410, encodeId=76153404103d, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Thu Aug 23 22:16:39 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267885, encodeId=5817126e885e0, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Aug 10 09:10:00 CST 2018, time=2018-08-10, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1643557, encodeId=4c61164355e06, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Sat Oct 20 10:10:00 CST 2018, time=2018-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843522, encodeId=fce1184352222, content=<a href='/topic/show?id=dab8100523bb' target=_blank style='color:#2F92EE;'>#颈动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100523, encryptionId=dab8100523bb, topicName=颈动脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Thu Mar 21 19:10:00 CST 2019, time=2019-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820295, encodeId=4656182029589, content=<a href='/topic/show?id=cc4b10056431' target=_blank style='color:#2F92EE;'>#颈动脉血管重建术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100564, encryptionId=cc4b10056431, topicName=颈动脉血管重建术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Sun Mar 24 06:10:00 CST 2019, time=2019-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708989, encodeId=3bd21e08989ed, content=<a href='/topic/show?id=1502333250f' target=_blank style='color:#2F92EE;'>#动脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33325, encryptionId=1502333250f, topicName=动脉血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=048f31575940, createdName=ms9833124466084992, createdTime=Sun Aug 19 11:10:00 CST 2018, time=2018-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971567, encodeId=243219e1567ff, content=<a href='/topic/show?id=797b8e67141' target=_blank style='color:#2F92EE;'>#药物使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87671, encryptionId=797b8e67141, topicName=药物使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Sat Mar 02 06:10:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044513, encodeId=c2fb20445137b, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Mar 21 04:10:00 CST 2019, time=2019-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340410, encodeId=76153404103d, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Thu Aug 23 22:16:39 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267885, encodeId=5817126e885e0, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Aug 10 09:10:00 CST 2018, time=2018-08-10, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1643557, encodeId=4c61164355e06, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Sat Oct 20 10:10:00 CST 2018, time=2018-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843522, encodeId=fce1184352222, content=<a href='/topic/show?id=dab8100523bb' target=_blank style='color:#2F92EE;'>#颈动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100523, encryptionId=dab8100523bb, topicName=颈动脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Thu Mar 21 19:10:00 CST 2019, time=2019-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820295, encodeId=4656182029589, content=<a href='/topic/show?id=cc4b10056431' target=_blank style='color:#2F92EE;'>#颈动脉血管重建术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100564, encryptionId=cc4b10056431, topicName=颈动脉血管重建术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Sun Mar 24 06:10:00 CST 2019, time=2019-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708989, encodeId=3bd21e08989ed, content=<a href='/topic/show?id=1502333250f' target=_blank style='color:#2F92EE;'>#动脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33325, encryptionId=1502333250f, topicName=动脉血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=048f31575940, createdName=ms9833124466084992, createdTime=Sun Aug 19 11:10:00 CST 2018, time=2018-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971567, encodeId=243219e1567ff, content=<a href='/topic/show?id=797b8e67141' target=_blank style='color:#2F92EE;'>#药物使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87671, encryptionId=797b8e67141, topicName=药物使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Sat Mar 02 06:10:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044513, encodeId=c2fb20445137b, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Mar 21 04:10:00 CST 2019, time=2019-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340410, encodeId=76153404103d, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Thu Aug 23 22:16:39 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267885, encodeId=5817126e885e0, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Aug 10 09:10:00 CST 2018, time=2018-08-10, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1643557, encodeId=4c61164355e06, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Sat Oct 20 10:10:00 CST 2018, time=2018-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843522, encodeId=fce1184352222, content=<a href='/topic/show?id=dab8100523bb' target=_blank style='color:#2F92EE;'>#颈动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100523, encryptionId=dab8100523bb, topicName=颈动脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Thu Mar 21 19:10:00 CST 2019, time=2019-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820295, encodeId=4656182029589, content=<a href='/topic/show?id=cc4b10056431' target=_blank style='color:#2F92EE;'>#颈动脉血管重建术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100564, encryptionId=cc4b10056431, topicName=颈动脉血管重建术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Sun Mar 24 06:10:00 CST 2019, time=2019-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708989, encodeId=3bd21e08989ed, content=<a href='/topic/show?id=1502333250f' target=_blank style='color:#2F92EE;'>#动脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33325, encryptionId=1502333250f, topicName=动脉血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=048f31575940, createdName=ms9833124466084992, createdTime=Sun Aug 19 11:10:00 CST 2018, time=2018-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971567, encodeId=243219e1567ff, content=<a href='/topic/show?id=797b8e67141' target=_blank style='color:#2F92EE;'>#药物使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87671, encryptionId=797b8e67141, topicName=药物使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Sat Mar 02 06:10:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044513, encodeId=c2fb20445137b, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Mar 21 04:10:00 CST 2019, time=2019-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340410, encodeId=76153404103d, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Thu Aug 23 22:16:39 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267885, encodeId=5817126e885e0, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Aug 10 09:10:00 CST 2018, time=2018-08-10, status=1, ipAttribution=)]
    2018-08-23 1e145228m78(暂无匿称)

    学习了,谢谢作者分享!

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1643557, encodeId=4c61164355e06, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Sat Oct 20 10:10:00 CST 2018, time=2018-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843522, encodeId=fce1184352222, content=<a href='/topic/show?id=dab8100523bb' target=_blank style='color:#2F92EE;'>#颈动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100523, encryptionId=dab8100523bb, topicName=颈动脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Thu Mar 21 19:10:00 CST 2019, time=2019-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820295, encodeId=4656182029589, content=<a href='/topic/show?id=cc4b10056431' target=_blank style='color:#2F92EE;'>#颈动脉血管重建术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100564, encryptionId=cc4b10056431, topicName=颈动脉血管重建术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Sun Mar 24 06:10:00 CST 2019, time=2019-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708989, encodeId=3bd21e08989ed, content=<a href='/topic/show?id=1502333250f' target=_blank style='color:#2F92EE;'>#动脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33325, encryptionId=1502333250f, topicName=动脉血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=048f31575940, createdName=ms9833124466084992, createdTime=Sun Aug 19 11:10:00 CST 2018, time=2018-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971567, encodeId=243219e1567ff, content=<a href='/topic/show?id=797b8e67141' target=_blank style='color:#2F92EE;'>#药物使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87671, encryptionId=797b8e67141, topicName=药物使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Sat Mar 02 06:10:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044513, encodeId=c2fb20445137b, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Mar 21 04:10:00 CST 2019, time=2019-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340410, encodeId=76153404103d, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Thu Aug 23 22:16:39 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267885, encodeId=5817126e885e0, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Aug 10 09:10:00 CST 2018, time=2018-08-10, status=1, ipAttribution=)]
    2018-08-10 zhaohui6731

相关资讯

他汀类药物幕后的无名英雄Alfred Alberts逝世

据《纽约时报》的一则新闻报道,美国批准的第一种降胆固醇的他汀类药物背后鲜为人知的英雄人物Alfred W. Alberts于6月16日在科罗拉多州去世,享年87岁。

Neurology:他汀类药物与自发性脑出血的关系

由此可见。该研究证实ICH的风险随着胆固醇水平的增加而降低,但表明他汀类药物的使用可能与ICH风险降低有关。

JCEM:服用他汀类药物与卒中患者骨质疏松症以及骨折风险降低有关

由此可见,服用他汀类药物与卒中患者骨质疏松症、髋部骨折和椎体骨折的风险降低有关。

Int J Cardiol:妊娠前期接触他汀类药物与胎儿室间隔缺损相关

由此可见,在妊娠前期接触他汀类药物与胎儿室间隔缺损有关。

Int J Cardiol:他汀类药物/依折麦布联合对慢性肾脏病患者冠状动脉粥样硬化斑块的影响!

由此可见,与非CKD相比,CKD患者采用阿托伐他汀/依折麦布强化降脂治疗与阿托伐他汀单药治疗相比可获得更强的冠状动脉斑块消退效应。

JAHA:75岁以下成人他汀类药物的使用情况和不良反应!

由此可见,对于一级预防,75岁以上的受试者他汀类药物的使用与75岁以下的受试者相似,但老年受试者较少接受高剂量他汀类药物用于二级预防。他汀类药物在老年和较年轻的受试者中也有相似的耐受性。